Organization: Health Canada
Year: 2023
Month: April
Request Number: A-2022-001354
Request Summary: Adverse Drug Reaction (ADR) for DEXILANT. Report number: E2B_05885170. ADRs for ENTYVIO. Report numbers: E2B_05957614, E2B_05947821, E2B_05932175, E2B_05955071, E2B_05935607, E2B_05932203, E2B_05951484. ADR for VEDOLIZUMAB. Report number: 001019420. ADR for Ondansetron. Report number: E2B_05923043.
Disposition: Disclosed in part
Number of pages: 1635